These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16902312)

  • 1. HIT on dialysis--when is it safe to re-challenge?
    Davenport A
    Nephron Clin Pract; 2006; 104(4):c149-50. PubMed ID: 16902312
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies.
    Hartman V; Malbrain M; Daelemans R; Meersman P; Zachée P
    Nephron Clin Pract; 2006; 104(4):c143-8. PubMed ID: 16902310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism.
    Zimrin AB; Warkentin TE
    Thromb Haemost; 2013 May; 109(5):971-3. PubMed ID: 23636478
    [No Abstract]   [Full Text] [Related]  

  • 4. Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?
    Matsuo T; Matsuo M; Ouga-Maruyama S
    Thromb Haemost; 2001 Oct; 86(4):1115-6. PubMed ID: 11686333
    [No Abstract]   [Full Text] [Related]  

  • 5. [Heparin-induced thrombocytopenia in hemodialysis. Case report and review of the literature].
    Henríquez F; Rodríguez A; Mora C; Sánchez-Deig E; Macía M; Navarro J
    Nefrologia; 2006; 26(6):734-7. PubMed ID: 17227252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients.
    Kato S; Takahashi K; Ayabe K; Samad R; Fukaya E; Friedmann P; Varma M; Bergmann SR
    Br J Haematol; 2011 Aug; 154(3):373-7. PubMed ID: 21615718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fatal central pulmonary embolism under heparin therapy: white-clot syndrome].
    Canova CR; Cantieni R; Zellweger U; Reinhart WH
    Schweiz Med Wochenschr; 1997 May; 127(18):762-5. PubMed ID: 9221488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin.
    Pohl C; Kredteck A; Bastians B; Hanfland P; Klockgether T; Harbrecht U
    Neurology; 2005 Apr; 64(7):1285-7. PubMed ID: 15824368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis.
    Randi ML; Tezza F; Scapin M; Duner E; Scarparo P; Scandellari R; Fabris F
    Acta Haematol; 2010; 123(3):140-5. PubMed ID: 20134155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thrombocytopenia can be HIT. Heparin treatment can cause low life-threatening thrombocyte levels].
    Själander A; Johansson L; Hillarp A; Bergqvist D; Tengborn L; Svensson P
    Lakartidningen; 2009 Mar 4-10; 106(10):682-5. PubMed ID: 19418688
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergency department awareness of heparin-induced thrombocytopenia: how frequently is risk assessment documented in patients with thrombosis?
    Levine RL; Funk R; Hergenroeder GW; Hursting MJ
    Am J Med Qual; 2010; 25(5):365-9. PubMed ID: 20522721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients.
    Matsuo T; Wanaka K; Miyasita K; Prechel M; Walenga JM
    Thromb Res; 2012 Apr; 129(4):474-8. PubMed ID: 22088491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis and clinical practice of heparin-induced thrombocytopenia and thrombosis].
    Matsuo T
    Rinsho Ketsueki; 2007 Jan; 48(1):9-18. PubMed ID: 17313072
    [No Abstract]   [Full Text] [Related]  

  • 14. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?
    Warkentin TE; Greinacher A; Koster A
    Ann Thorac Surg; 2009 May; 87(5):1633-40. PubMed ID: 19379937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for heparin-induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage.
    Alaraj A; Wallace A; Mander N; Aletich V; Charbel FT; Amin-Hanjani S
    Neurosurgery; 2011 Nov; 69(5):1030-6. PubMed ID: 21670717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.
    Levy JH; Tanaka KA; Hursting MJ
    Anesth Analg; 2007 Sep; 105(3):570-82. PubMed ID: 17717208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients.
    Chang JJ; Parikh CR
    Semin Dial; 2006; 19(4):297-304. PubMed ID: 16893407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin-induced thrombocytopenia syndrome and thrombosis in patients undergoing periodic haemodialysis].
    Gregorini G; Bellandi D; Martini G; Volpi R
    G Ital Nefrol; 2002; 19(6):672-92. PubMed ID: 12508172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis.
    Davenport A
    Am J Kidney Dis; 2009 Aug; 54(2):361-74. PubMed ID: 19481318
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis.
    Nakamoto H; Shimada Y; Kanno T; Wanaka K; Matsuo T; Suzuki H
    Hemodial Int; 2005 Oct; 9 Suppl 1():S2-7. PubMed ID: 16223438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.